Lantern Pharma Gets Orphan Drug Designation for Mantle Cell Lymphoma Candidate

 

• The Orphan Drug Designation strengthens LP-284’s clinical development path and provides the opportunity for additional market exclusivity and commercial protection.

• Lantern is anticipating filing the IND with the FDA and initiating a first-in-human Phase 1 trial for LP-284 in B-cell non-Hodgkin’s lymphomas (NHL), including mantle cell lymphoma (MCL), by mid 2023.

• In the US, MCL is diagnosed in approximately 4,500 patients each year and has an estimated annual market potential of $600 million.

https://finance.yahoo.com/news/fda-grants-lantern-pharma-orphan-135900945.html